Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension (OHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04474899
Recruitment Status : Recruiting
First Posted : July 17, 2020
Last Update Posted : September 27, 2021
Sponsor:
Collaborator:
The University of Western Australia
Information provided by (Responsible Party):
Dr Markus Schlaich, Royal Perth Hospital